Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Caris Life Sciences reported Q3 2026 revenue of $275.4 million, up 27% year over year, and raised full-year 2026 revenue guidance to $1.04–$1.05 billion, implying 28%–29% growth. Clinical cases rose 21% to approximately 61,500, while net income fell to $15.3 million from $24.3 million, adjusted EBITDA declined to $44.4 million from $51.2 million, and operating cash flow shifted to a $22.2 million outflow from a $62.4 million inflow. The quarter also included launches of therapy-response monitoring and enhanced therapy-selection offerings; up to $100 million is authorized for share repurchases, with $72.1 million remaining.

Analysis

The quality of growth is the key issue, not the headline top-line rate. Q3 operating expenses grew faster than revenue, gross margin slipped, and adjusted EBITDA declined year over year: added commercial, R&D and launch spend is not yet translating into operating leverage. The raised annual revenue range requires roughly $285–295m in Q4, modestly above Q3, but the volume outlook is only about 20% growth; monitor whether ASP and mix must do more of the work.

Cash conversion is the second-order risk. Q3 operating cash use and negative free cash flow reflect inventory and investment, while supplies have increased materially since year-end. This could be launch preparation rather than demand weakness, but repeated inventory growth without faster case conversion would tie up cash and raise obsolescence risk. The remaining buyback authorization may support near-term sentiment, yet repurchases alongside negative FCF and expansion spending deserve scrutiny.

Near term, guidance and case growth are supportive; over 1–3 months, the call should clarify Q4 volume/ASP, payer reimbursement, and launch uptake. Over 6–18 months, response monitoring and MRD could widen the addressable testing journey, but validation, coverage and adoption—not assay launches or database scale alone—determine monetization. Foundation Medicine and Tempus are relevant competitive checks on differentiation and pricing. Contrarian read: investors may over-credit AI/product breadth while underweighting cash conversion and incremental operating costs; conversely, the cash draw may be temporary if inventory converts as launches scale.

Key Decisions for Investors

• Keep CAI on an earnings-quality watchlist rather than chase the guidance raise. Reassess after the call for a bridge from case growth and ASP to Q4 revenue, plus evidence that gross margin stabilizes.
• Use inventory and cash conversion as the 1–3 month tripwire: track supplies, receivables, operating cash flow and free cash flow next quarter. A further inventory build without case growth near guidance would weaken the launch-investment thesis.
• Treat the buyback as a sentiment support, not a floor. Verify actual repurchase pace and liquidity priorities; reconsider the cautious stance if buybacks accelerate while free cash flow remains negative.
• Avoid a directional trade without valuation and post-results price action. A sustained deterioration in gross margin or a guidance/volume reset would be a clearer downside catalyst; payer coverage and measurable uptake of newer assays would be upside confirmation.